- Home
- BNY vs THRD Comparison
BNY vs THRD Comparison
Compare BNY & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNY
- THRD
- Stock Information
- Founded
- BNY 2001
- THRD 2019
- Country
- BNY United States
- THRD United States
- Employees
- BNY N/A
- THRD N/A
- Industry
- BNY Trusts Except Educational Religious and Charitable
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- BNY Finance
- THRD Health Care
- Exchange
- BNY Nasdaq
- THRD Nasdaq
- Market Cap
- BNY 232.5M
- THRD 238.7M
- IPO Year
- BNY N/A
- THRD 2022
- Fundamental
- Price
- BNY $9.61
- THRD $5.42
- Analyst Decision
- BNY
- THRD Hold
- Analyst Count
- BNY 0
- THRD 3
- Target Price
- BNY N/A
- THRD $5.00
- AVG Volume (30 Days)
- BNY 52.7K
- THRD 251.2K
- Earning Date
- BNY 01-01-0001
- THRD 08-07-2025
- Dividend Yield
- BNY 3.93%
- THRD N/A
- EPS Growth
- BNY N/A
- THRD N/A
- EPS
- BNY N/A
- THRD N/A
- Revenue
- BNY N/A
- THRD N/A
- Revenue This Year
- BNY N/A
- THRD N/A
- Revenue Next Year
- BNY N/A
- THRD N/A
- P/E Ratio
- BNY N/A
- THRD N/A
- Revenue Growth
- BNY N/A
- THRD N/A
- 52 Week Low
- BNY $8.60
- THRD $3.18
- 52 Week High
- BNY $10.80
- THRD $16.02
- Technical
- Relative Strength Index (RSI)
- BNY 42.94
- THRD 68.70
- Support Level
- BNY $9.56
- THRD $5.41
- Resistance Level
- BNY $9.69
- THRD $5.52
- Average True Range (ATR)
- BNY 0.08
- THRD 0.05
- MACD
- BNY 0.01
- THRD -0.01
- Stochastic Oscillator
- BNY 26.32
- THRD 64.29
About BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.